Diagnosing and Treating Drug-Induced Osteonecrosis of the Jaw, and TMJ and Tooth Pain

Preventing and treating necrosis of the jaw resulting from drugs taken for osteoporosis is an important consideration for today’s clinicians in determining the appropriate dental care.

As our patient population ages, more and more patients, especially females, are taking drugs for osteopenia and osteoporosis. These drugs impair osteoclastic bone resorption, and therefore bone renewal, thereby retaining old bone and reducing its ability to turn over. Because the alveolar bone in the jaws turns over faster than any other bone in the adult skeleton, it is the focal point for drug-induced osteonecrosis of the jaws (DIONJ). This condition is especially important when considering extractions, osseous surgery and the placement of dental implants.

The following discussion is summarized from a Position Paper on Drug-Induced Osteonecrosis of the Jaws (DIONJ) by Robert E. Marx, DDS, and Ramzy Tursun, DDS, University of Miami Division of Oral and Maxillofacial Surgery, September 27, 2016.

The current drugs that place osteopenia and osteoporosis patients at risk for DIONJ are the oral bisphosphonates, alendronate (Fosamax and generic equivalents), zoledronic acid, ibandronate, and their generic substitutes. These drugs are used to prevent and treat osteoporosis and osteopenia and are often prescribed for the treatment of conditions such as Paget’s disease and hypercalcemia of malignancy.
valents), residronate (Actonel and Atelvia) and ibandronate (Boniva); the subcutaneously-injected denosumab (Prolia and Xgeva); and the intravenous bisphosphonate zoledronate (Reclast and Zometa.)

Of the oral bisphosphonates, alendronate (Fosamax) is the drug linked to 96 percent of cases of DIONJ compared to three percent of cases caused by residronate (Actonel) and one percent of cases caused by ibandronate (Boniva). This is mostly due to the fact that alendronate is marketed at twice the dose of all other bisphosphonates (70mg/week), while it has the same absorption, distribution, and the same potency as the others.

Although zoledronate as Reclast is relatively new, and only 5mg is delivered by IV only once yearly for osteoporosis, it is causing several cases of DIONJ. This is because the half life in bone of 11 years is the same for all the bisphosphonates, and the IV infusion loads the bone 140 times more than any oral bisphosphonate.

Therefore, dental professionals must realize that, although some DIONJ cases may occur sooner, the significant DIONJ risk for an oral bisphosphonate begins at about three years of weekly dosing, and with IV Reclast at about the fourth yearly dose.

Those osteopenia/osteoporosis patients converted to Reclast after taking an oral bisphosphonate are at risk for DIONJ before the fourth dose, and may need a drug holiday longer than nine months.

The FDA has recommended that no one needs to take a bisphosphonate for more than five years.

Denosumab (Prolia and Xgeva) as a RANK ligand inhibitor does not seem to bind to bone or accumulate in bone as do bisphosphonates, and has a half life in bone of 26 days. Therefore, if this drug has been taken for less than three years, discontinuation with a shorter drug holiday of three months is adequate.

Switching from a bisphosphonate to denosumab causes necrosis relatively frequently and should be avoided.

Discussions with the patient’s physician about the choice of medicine and dosage is very important.

See the Spring 2017 issue of The PerioDontaLetter for a table summarizing the many bisphosphonates and monoclonal antibodies which are used to treat osteoporosis and bone cancer. The table includes the route these drugs are administered, and their likelihood of causing drug-induced osteonecrosis of the jaw.

Patients on IV bisphosphonates for the treatment of cancer are at much greater risk of DIONJ than patients taking oral bisphosphonates.

Prevention -- What to Do and What Not to Do

The initiating event for DIONJ is surgery involving the alveolar bone: tooth removals (62%), osseous periodontal surgery (5.6%), dental implants (2.2%), bone biopsy (1.1%), and apical resective endodontic therapy (0.5%) with 29% spontaneous development (more commonly from the higher IV doses used to treat bone cancer patients). Occlusal trauma can also be a factor in lower lingual necrosis.

For those patients requiring bone surgery who are taking an oral bisphosphonate, it may be reasonable to assess the bone turnover suppression by requesting a morning fasting serum c-terminal telopeptide (CTX) test. (Many experts have questioned the usefulness of this test.) A value of 150 pg/ml or greater is consistent with bone healing, if the test is not invalidated by cancer, steroids or methotrexate.

When the CTX test is above 150 pg/ml, the planned alveolar bone surgery can be accomplished and a three-month drug holiday requested from the prescribing physician to cover the healing period. If the CTX value is below 150 pg/ml, a drug holiday prior to performing alveolar bone surgery, placing implants, or orthodontic treatment is advisable.

For patients who have taken an oral bisphosphonate for more than three years, the initial CTX is usually below the 150 pg/ml level. For such patients, a longer drug holiday is usually necessary. Many are required to be as long as nine months or more.

Treating DIONJ in the Osteopenia/ Osteoporosis Patient

Exposed bone represents necrotic bone. If the offending drug is continued, the area of exposed bone is likely to increase, and secondary areas of exposed bone may develop. It is advised to request a drug holiday from the prescribing physician.

Studies have shown that a drug holiday of nine months will result in a spontaneous sequesstration and exfoliation of the exposed bone, followed by mucosal healing in 50 percent of cases. These cases are usually the smaller areas of exposed bone. During this drug holiday, use 0.12 percent chlorhexidine oral rinses three times daily to prevent secondary infection.

If secondary infection develops, penicillin VK 500mg QID, or doxycycline 100mg once daily, are the best antibiotics to use. For larger areas of osteonecrosis, referral to an oral surgeon is indicated.
needs to take a bisphosphonate for more drug holiday longer than nine months. before the fourth dose, and may need a converted to Reclast after taking an oral occur sooner, the significant DIONJ risk for the same for all the bisphosphonates, and the because the half life in bone of 11 years is is causing several cases of DIONJ. This is by IV only once yearly for osteoporosis, it Although zoledronate as Reclast is mandible after an extraction severe osteonecrosis of the initiating event for DIONJ is sur- Patients on IV bisphosphonates for the occlusal trauma in bone surgery, placing implants, or orthodontic therapy (0.5%) with 29% sponta-

treatment of cancer are at much greater risk of DIONJ than patients taking oral drugs. The initiating event for DIONJ is sur-

Diagnosing and Treating Tooth Pain

A symptomatic tooth may have pain of pulpal and/or periodontal origin. The nature of that pain is the first clue in determining the etiology of such a problem. Radiographic and clinical evaluation is essential in arriving at the diagnosis.

If the pain is sharp when biting and lasts only a few seconds, the patient may have a crack in the tooth. If the crack is confined to the coronal aspect of the tooth, the tooth can often be saved without endodontic therapy and with a full coverage restoration. If the crack involves the pulp, the problem is often resolved with endodontic and restorative therapy. Crown lengthening below the fracture line and a full coverage restoration will usually resolve the problem. If the tooth has a large crack or a vertical root fracture, it will usually have to be extracted and replaced by an implant or bridge.

Endodontic Treatment

If the pain is severe or sharp, keeps the patient up at night, and is exacerbated by thermal changes lasting more than 15 seconds, it most likely means the pulp of the tooth is dying and the patient will need endodontic treatment. Other indications that the tooth may need endodontic
root sensitivity is eating lots of fruit or drinking fruit juices. Fruit is obviously good for us, but it also causes lots of cavities and root sensitivity.

Most fruits are very acidic and contain lots of fructose. The acids in fruits are responsible for much of the root sensitivity that we see.

Other acidic causes of sensitivity are vinegar, yogurt, sports and soft drinks, and tea. Check the patient's diet closely for acidic content if they are experiencing root sensitivity.

These acids open up dentinal tubules in the root and allow cold, hot or touch stimuli a pathway into the pulp of the tooth causing pain. The pain is usually short lived.

If the pain lasts for more than a few seconds, the pulp may be infected and endodontic treatment may be indicated.

Drinking acidic beverages through a straw, and eating and swallowing fruits quickly will minimize acidic exposure to tooth roots. Rinsing with water immediately after ingesting will dilute the acidic effect.

Patients should wait to brush for at least 30 minutes as the acids soften the roots, making them more susceptible to wear and dental abrasion.

Sipping acidic drinks is especially damaging by keeping acid on the root. Drinking quickly reduces the time of acid demineralization so advise your patients: "gulp don't sip" to reduce sensitivity.

The fructose in fruits is closely related to sucrose (sugar). It will cause cavities just like all sugar products, including and especially Altoids, Tic Tacs, and other sugar-containing breath mints.

To help control sensitivity, patients can use toothpastes containing potassium nitrate and fluoride like Sensodyne, and rinse with fluoride rinses like Act Complete.

Over-the-counter Sensi-Strips can be applied daily for ten minutes to block the tubules with oxalate crystals. More potent prescription fluoride pastes are available which will protect roots and also reduce caries.

In the office, fluoride varnish can be applied. Even more effective are light-cured coatings performed in office with Vanish XT or Seal and Protect.

If root sensitivity continues to be a problem, periodontal therapy may be possible to re-cover the exposed roots.

If root coverage is not possible, the sensitive area can be bonded. In rare cases, endodontic therapy may be required to resolve the sensitivity.

Causes and Treatment of Root Sensitivity

One of the main causes of root sensitivity is eating lots of fruit or drinking fruit juices. Fruit is obviously good for us, but it also causes lots of cavities and root sensitivity.

If prior endodontic treatment has been completed and pain returns, endodontic retreatment or endodontic surgery may be considered. If these approaches are not successful, the tooth may need to be extracted and replaced by a fixed prosthesis or an implant.

Periodontal Problems

If the pain is dull and less severe, periodontal etiology should be considered. Usually the patient can identify the specific location of the pain in contrast to pulp pain which can be difficult to localize. Exudate and pocket depth of at least 5mm or more is usually present.

Periodontal therapy with debridement, irrigation, and topical antibiotics will usually manage the acute infection. For larger infections, systemic antibiotics are often needed. Later, conventional periodontal therapy is usually required.

Root Sensitivity

If the pain is made worse by thermal changes lasting only a few seconds without pain on mastication, the source may be root sensitivity. Root sensitivity can be treated by desensitizing medications.

Conclusion

Because of the complexity of these infections, an interdisciplinary approach with good collaboration between the periodontist, the restorative dentist, and the endodontist is critical to achieving the correct diagnosis and determining the appropriate treatment for jaw pain caused by these three conditions.